Rocket Pharmaceuticals Investor Presentation — May 2022

Document content

S E E K I N G G E N E T H E R A P Y C U R E SRocket Program Updates Following ASGCT 2022

Danon Disease, Pyruvate Kinase Deficiency, Fanconi Anemia, and Leukocyte Adhesion Deficiency -I

Chief Executive Officer

Cautionary Statement Regarding Forward -Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation , Rocket's

expectations regarding its guidance for 2022 in light of COVID -19, the safety, effectiveness and timing of product candidates th at Rocket

may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency -I (LAD -I), Pyruvate Kinase Deficiency (PKD), Infantile

Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre -clinical studies and cl inical

trials, may constitute forward -looking statements for the purposes of the safe harbor provisions under the Private Securities Li tigation

Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not

place reliance on these forward -looking statements, which often include words such as "believe," "expect," "anticipate," "intend ,"

"plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms.

Although Rocket believes that the expectations reflected in the forward -looking statements are reasonable, Rocket cannot guarant ee

such outcomes. Actual results may differ materially from those indicated by these forward -looking statements as a result of vari ous

important factors, including, without limitation, Rocket's ability to monitor the impact of COVID -19 on its business operations and take

steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of

Rocket’s ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our exp ectations

regarding the delays and impact of COVID -19 on clinical sites, patient enrollment, trial timelines and data readouts, our expect ations

regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initia tion, timing

and progress of pre -clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for dev elopment,

manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, aswell

as those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Annual Report on Form 10 -K for the year e nded